IBA

IBA Sells Prototype of Next Generation Carbon Therapy System

    LOUVAIN- LA-NEUVE, Belgium, September 2, 2010 (ots/PRNewswire) - IBA (Ion Beam Applications S.A.), developer of equipment and pharmaceuticals dedicated to cancer diagnosis and treatment, announced today that it has sold the prototype of its next generation carbon therapy system to the French company CYCLHAD (un CYCLotron pour l'HADronthérapie, or a Cyclotron for Hadron Therapy). CYCLHAD is a joint venture between IBA, SAPHYN (SAnté et PHYsique Nucléaire, or Nuclear Health and Physics, a semi-public company in Caen, France) and financial partners. Simultaneously, IBA has signed a research and development agreement with SAPHYN to jointly develop the potential of carbon beam therapy. These agreements will enable IBA to continue its commitment towards providing next generation cancer therapy techniques and personalized patient care.

    Under the terms of the sales agreement, IBA will provide CYCLHAD with the prototype of its next generation carbon therapy system based on an advanced 400 MeV (millions of electron volts) superconducting isochronous cyclotron able to accelerate carbon ions used in cancer therapy. IBA will be responsible for the research, development and validation of all technical and scientific equipment, and for the installation of the cyclotron in CYCLHAD's research center in Caen, along with one fixed beam clinical research room and one fixed beam physics research room. IBA will also provide CYCLHAD with a 15-year service contract on the system. IBA will receive a payment of between 60 and 70 million Euros for the equipment and services from CYCLHAD. The contract signed today is still contingent on CYCLHAD obtaining the necessary bank financing. As the system is a prototype, this contract will have a very limited impact on IBA profits.

    "Carbon shows enormous potential as a powerful solution for difficult problems in the radiotherapy of cancer. Its ability to treat tumors that have had the reputation of being radiation-resistant can be crucial when treating cancers in areas such as the head and neck," said Yves Jongen, founder and CRO of IBA. "As a pioneer in proton therapy, IBA is dedicated to making the most accurate cancer treatments available to radiation oncologists and patients through new developments that maximize our expertise. This is also the first IBA system using the technology of superconducting magnets which is likely to revolutionize cyclotron technology in the coming years. IBA is pleased to partner with public and semi-public institutions in the Caen area and share the same mission to develop novel techniques that could benefit patient health on a global scale."

    IBA is a leader in proton therapy, having sold 18 proton therapy systems worldwide. A form of radiotherapy, proton therapy delivers a precise dose of protons to a tumor to kill cancer cells while sparing healthy surrounding tissue. IBA is now entering into new treatment techniques such as carbon therapy, a more powerful and precise method to treat tumors, in particular ones which show resistance to radiology treatments. Higher doses can be delivered to the tumor without increasing the risk of side effects and long term complications, thereby minimizing the number of treatment sessions needed and improving treatment results and patient quality of life.

    About IBA  

    IBA develops and markets leading-edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization.

    Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index.

    (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).  

    Website: http://www.iba-worldwide.com

ots Originaltext: IBA
Im Internet recherchierbar: http://www.presseportal.ch

Contact:
CONTACT:  Media contacts: Christina Aplington, Ballou PR for
IBA,+33-1-42229365, christina@balloupr.com



Weitere Meldungen: IBA

Das könnte Sie auch interessieren: